Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Revenue (2017 - 2025)

Neurocrine Biosciences' Revenue history spans 15 years, with the latest figure at $805.5 million for Q4 2025.

  • For Q4 2025, Revenue rose 28.33% year-over-year to $805.5 million; the TTM value through Dec 2025 reached $2.9 billion, up 21.45%, while the annual FY2025 figure was $2.9 billion, 21.45% up from the prior year.
  • Revenue reached $805.5 million in Q4 2025 per NBIX's latest filing, up from $794.9 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $805.5 million in Q4 2025 to a low of -$6.6 million in Q4 2021.
  • Average Revenue over 5 years is $452.4 million, with a median of $475.8 million recorded in 2023.
  • Peak YoY movement for Revenue: crashed 102.66% in 2021, then skyrocketed 6342.42% in 2022.
  • A 5-year view of Revenue shows it stood at -$6.6 million in 2021, then surged by 6342.42% to $412.0 million in 2022, then grew by 25.05% to $515.2 million in 2023, then grew by 21.84% to $627.7 million in 2024, then increased by 28.33% to $805.5 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Revenue are $805.5 million (Q4 2025), $794.9 million (Q3 2025), and $687.5 million (Q2 2025).